Ventyx Biosciences EBIT

As of the most recent data (September 2025), VTYX shows a EBIT of $-120M. That compares with $-160M in the prior-year period — up 28.7% year over year. That is below the sector sector average of $-22M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VTYX's EBIT is now $-120M (was $-160M) — a 28.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ventyx Biosciences is outperforming or lagging.

The its sector sector average EBIT is about $-22M. Ventyx Biosciences is at $-120M, which is lower that average. That is roughly 443.5% below the sector mean. Use the comparison chart on this page to see how VTYX stacks up against individual peers as well.

Tracking VTYX's ebit over time shows whether Ventyx Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-120M That compares with $-160M in the prior-year period — up 28.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Ventyx Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-120M) with ownership activity and broader fundamentals.